Provided by Tiger Trade Technology Pte. Ltd.

Defiance Daily Target 2X Long LLY ETF

25.68
+1.305.33%
Pre-market: 25.840.1623+0.63%04:22 EDT
Volume:462.96K
Turnover:11.92M
Market Cap:88.98M
PE:- -
High:26.42
Open:24.84
Low:24.82
Close:24.38
52wk High:31.19
52wk Low:14.51
Shares:3.47M
Float Shares:3.47M
Volume Ratio:1.86
T/O Rate:13.36%
Dividend:0.70
Dividend Rate:2.74%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Eli Lilly - Zepbound 10 Mg and 15 Mg Show Comparable Adverse Event Discontinuation Rates to Wegovy Hd

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Shows 4.5% Greater Weight Loss than Wegovy Hd in Adults with Obesity

THOMSON REUTERS
·
Sep 29

Lilly's Zepbound (Tirzepatide 10 Mg and 15 Mg) was Associated with More Weight Loss than Wegovy Hd (Semaglutide Injection 7.2 Mg) in a New Indirect Treatment Comparison

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound Achieves 20.2% Weight Reduction vs 13.7% for Wegovy at 72 Weeks

THOMSON REUTERS
·
Sep 29

Eli Lilly - Zepbound 15 Mg Users Have over Three Times the Odds of 20% Weight Reduction vs Wegovy Hd

THOMSON REUTERS
·
Sep 29

Lilly Touts Foundayo Advantage over Novo's Ozempic Pill in Diabetes Analysis

Reuters
·
Sep 29

Novo Nordisk Says Ozempic Shows Lower Risk of Cardiovascular Events Compared to Eli Lilly's Mounjaro

Reuters
·
Sep 29

Eli Lilly announces positive results from study of Foundayo 17.2 mg

TIPRANKS
·
Sep 29

Eli Lilly's Foundayo 17.2 Mg was Associated with 1.5% Greater Weight Loss at 52 Weeks

Reuters
·
Sep 29

Lilly Says Foundayo 17.2 Mg Outperforms Oral Semaglutide 25 Mg on Weight Loss, A1C in Indirect Comparison Study

Reuters
·
Sep 29

Eli Lilly - Foundayo 17.2 Mg Shows 1.5% Greater Weight Loss and 0.3% Greater A1c Reduction at 52 Weeks

THOMSON REUTERS
·
Sep 29

$20 Billion In Deals And Counting: Lilly's CEO Targets The "White Space" Of Science For Larger M&A

Options & Short Sell
·
Sep 29

DexCom’s Oura Bet: Potential Investment Gains Meet a Bigger Healthcare Opportunity

Bellwether Stocks Movement
·
Sep 29

AstraZeneca To Invest $2 Billion In Summit And Co-Develop Drugs; Shares Jump After Hours

Options & Short Sell
·
Sep 29

Sector Update: Healthcare

MT Newswires Live
·
Sep 29

Market Chatter: Eli Lilly CEO Plans Larger Deals to Target New Disease Areas

MT Newswires Live
·
Sep 29

Lilly CEO Eyes Bigger Deals in Hunt for Pharma's 'white Spaces' - Bloomberg News

Reuters
·
Sep 29

Eli Lilly CEO tells Bloomberg sees more deals in untapped areas

TIPRANKS
·
Sep 29

US Drugmakers Turn to China for Licensing Deals

Reuters
·
Sep 28

Taking Ozempic? a Routine Eye Exam Could Help You Understand Your Risk for Vision Loss

Dow Jones
·
Sep 28